Injection market will face a shuffle, TOP20 varieties may change days?

[
pharmacy network market analysis] May 14, the State Food and Drug Administration announced the official launch of consistency evaluations drug injectionClear announcement, in addition to sodium chloride injection, glucose injection, glucose and sodium chloride injection, water for injection, part of the radiopharmaceutical (e.g., [99mTc] technetium) without having to carry out other varieties consistency evaluations, have been listed Kayaku injection imitation pharmaceutical, not in accordance with the original drug quality and efficacy agreement in principle approval of the species are required to carry out evaluation of conformityWith the release of the document, as well as with the amount of advance procurement policies, injections or will enter "+ Jicai evaluation of consistency" in the new environment, over 600 billion market will face a reshufflemeters within the network data show that in 2019 Chinese public medical institutions terminal of injection drug TOP20 products are a large variety of over 3 billion total sales of over 100 billion yuan11 injection has increased sales value 2018, which, dezocine injection, injection Meropenem, Cefoperazone Sodium sulbactam (2: 1), iodixanol injection growth reached two numberSpecifically, the Yangtze River dezocine injection in 2019 in China terminal sales in public medical institutions 67.83 billion yuan, up 17.86 percent growth rateStatistics show that dezocine is a potent opioid analgesic by Wyeth-Ayerst laboratory research and development, in 1990 in the United States in 2009, the production of the Yangtze River dezocine first injection simulation marketSumitomo meropenem for injection in 2019 in China terminal sales in public medical institutions to 6.019 billion yuan, an increase of 12.21 percent, the company accounted for nearly forty percent of domestic market shareStatistics show that the variety is suitable for adults and children from single or multiple bacteria sensitive to meropenem caused by infectionCefoperazone SodiumPfizer sulbactam sodium (2: 1) accounts for ninety percent of domestic market share in 2019 in China terminal sales in public medical institutions to 4.759 billion yuan, an increase of 15.82 %Statistics show that Cefoperazone sodium sulbactam (2:1) as anti-infective agents, for the treatment of sensitive bacteria caused by respiratory infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, bone and joint infections, septicemia, meningitisiodixanol injection Hengrui Medicine in 2019 in China terminal sales in public medical institutions to 3.685 billion yuan, an increase of 26.92 percent, Henry accounted for about half of domestic market shareData show iodixanol isotonic with blood is a diagnostic X-ray contrast agent having a high safety heart, kidney resistance, good patient comfort, and less interference cardiopulmonary circulation, etc., and cardiac nerve vascular system, check the abdomen, pelvic organs such lesions play a role in improving lesion detection rate and diagnostic identification, approved and recommended by numerous domestic and international clinical guidelines and expert consensusis worth noting that, in this 20 injections, currently only for injection pemetrexed disodium, docetaxel injection had a comment enterprises But in addition to sodium for injection cefoperazone sulbactam Pfizer: outside (21), other varieties are submitted by enterprises to evaluate the agreement or supplemental application under the new classification newspaper production industry believes that consistency with the start of the evaluation of drug injection, except for consistency in evaluation carried out without species such as Sodium Chloride Injection, Dextrose Injection, or part of the product TOP20 product sales impact, and therefore for the relevant companies, over-evaluation of the need to pay close attention.